CD4 and cancer: Moreover, after being treated with the HRMTF NPs, the intratumoral helper T cells (CD3+CD4+) and cytotoxic T cells (CD3+CD8+) were both largely increased relative to those in the control group (Fig. S17), demonstrating that the HRMTF NPs could finally stimulate the local immune system for cancer therapy.